The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

Adam L. Boxer, Michael Gold, Edward Huey, William T. Hu, Howard Rosen, Joel Kramer, Fen Biao Gao, Edward A. Burton, Tiffany Chow, Aimee Kao, Blair R. Leavitt, Bruce Lamb, Megan Grether, David Knopman, Nigel J. Cairns, Ian R. Mackenzie, Laura Mitic, Erik D. Roberson, Daniel Van Kammen, Marc CantillonKathleen Zahs, George Jackson, Stephen Salloway, John Morris, Gary Tong, Howard Feldman, Howard Fillit, Susan Dickinson, Zaven S. Khachaturian, Margaret Sutherland, Susan Abushakra, Joseph Lewcock, Robert Farese, Robert O. Kenet, Frank Laferla, Steve Perrin, Steve Whitaker, Lawrence Honig, Marsel M. Mesulam, Brad Boeve, Murray Grossman, Bruce L. Miller, Jeffrey L. Cummings

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences